Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Study of real-world clinical practice around AL amyloidosis in the United States finds most patients received 2 or more lines of treatment; 1/3 1st line patients had heme response; median PFS was 41.4 months, EFS 24.4 months.”
Authors: Sophia Li, Anita D’Souza, Suzanne Lentzsch, Faiza Zafar, Irina Pivneva, Talissa Watson, Annie Guerin, Shaji Kumar.
More posts featuring Robert Orlowski.
